Anna Sureda

33.8k total citations · 3 hit papers
465 papers, 11.7k citations indexed

About

Anna Sureda is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Anna Sureda has authored 465 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 236 papers in Oncology, 205 papers in Pathology and Forensic Medicine and 191 papers in Hematology. Recurrent topics in Anna Sureda's work include Lymphoma Diagnosis and Treatment (203 papers), Hematopoietic Stem Cell Transplantation (103 papers) and CAR-T cell therapy research (88 papers). Anna Sureda is often cited by papers focused on Lymphoma Diagnosis and Treatment (203 papers), Hematopoietic Stem Cell Transplantation (103 papers) and CAR-T cell therapy research (88 papers). Anna Sureda collaborates with scholars based in Spain, United Kingdom and France. Anna Sureda's co-authors include Rodrigo Martino, Salut Brunet, Jorge Sierra, Norbert Schmitz, Jakob Passweg, Peter Dreger, Carmen Canals, Rafael F. Duarte, Mohamad Mohty and Helen Baldomero and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Anna Sureda

435 papers receiving 11.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 477 citations Anna Sureda et al. profile →
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

2021 212 citations Martin Hutchings, David Lewis et al. profile →
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

2022 159 citations John A. Snowden, Isabel Sánchez‐Ortega et al. Bone Marrow Transplantation profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Anna Sureda	5.6k	5.0k	4.5k	2.3k	2.2k	465	11.7k
Koen van Besien	4.4k 0.8×	6.9k 1.4×	2.9k 0.6×	2.6k 1.1×	3.2k 1.5×	354	12.0k
Nöel Milpied	5.3k 0.9×	6.1k 1.2×	4.2k 0.9×	2.8k 1.2×	2.7k 1.2×	423	13.9k
Jürgen Finke	3.8k 0.7×	6.9k 1.4×	2.6k 0.6×	2.7k 1.2×	3.4k 1.6×	396	12.9k
Gregor Verhoef	3.0k 0.5×	3.1k 0.6×	3.5k 0.8×	2.3k 1.0×	1.2k 0.5×	187	9.4k
Richard F. Ambinder	9.4k 1.7×	2.6k 0.5×	5.9k 1.3×	1.6k 0.7×	3.0k 1.4×	348	15.1k
Mitchell S. Cairo	4.5k 0.8×	4.8k 1.0×	3.3k 0.7×	2.6k 1.1×	3.0k 1.4×	507	14.9k
Chitra Hosing	3.2k 0.6×	5.1k 1.0×	1.8k 0.4×	1.5k 0.6×	2.2k 1.0×	372	8.9k
Eckhard Thiel	3.1k 0.5×	2.5k 0.5×	2.7k 0.6×	2.7k 1.1×	3.4k 1.6×	260	11.9k
Paolo Anderlini	3.4k 0.6×	7.5k 1.5×	1.8k 0.4×	2.1k 0.9×	3.1k 1.4×	210	10.3k
Augustin Ferrant	3.1k 0.5×	6.5k 1.3×	1.7k 0.4×	2.3k 1.0×	1.8k 0.8×	225	10.9k

Countries citing papers authored by Anna Sureda

Since Specialization

Citations

This map shows the geographic impact of Anna Sureda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Sureda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Sureda more than expected).

Fields of papers citing papers by Anna Sureda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Sureda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Sureda. The network helps show where Anna Sureda may publish in the future.

Co-authorship network of co-authors of Anna Sureda

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Sureda. A scholar is included among the top collaborators of Anna Sureda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Sureda. Anna Sureda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bazarbachi, Ali, Ambroise Marçais, Arian Laurence, et al.. (2026). Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP. Bone Marrow Transplantation. 61(3). 341–346.

Hutchings, Martin, Anna Sureda, Francesc Bosch, et al.. (2025). Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Journal of Clinical Oncology. 43(36). 3788–3798.

Renders, Simon, Hervé Finel, William Townsend, et al.. (2024). Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study. Blood Advances. 8(21). 5571–5578.

Laporte-Amargós, Júlia, Francisco Carmona-Torre, Pedro Puerta‐Alcalde, et al.. (2024). Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial. Clinical Microbiology and Infection. 31(2). 211–219. 1 indexed citations

Sánchez‐Guijo, Fermín, Joaquim Vives, Christian Chabannon, et al.. (2024). Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT). Cytotherapy. 26(7). 681–685. 10 indexed citations

Brody, Joshua, David Belada, Régis Costello, et al.. (2024). Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.. Journal of Clinical Oncology. 42(16_suppl). 7037–7037. 3 indexed citations

Paviglianiti, Annalisa, et al.. (2024). Telemedicine With Wearable Technologies in Patients Undergoing Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy (TEL-HEMATO Study): Prospective Noninterventional Single-Center Study. JMIR Formative Research. 8. e55918–e55918. 3 indexed citations

Velasco, Roser, Alberto Mussetti, Macarena Villagrán‐García, & Anna Sureda. (2023). CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?. Frontiers in Neurology. 14. 1144414–1144414. 32 indexed citations

Okamoto, Shinichiro, Minako Iida, Nada Hamad, et al.. (2023). American Society of Transplantation and Cellular Therapy International Affair Committee: Report of the Third Workshop on Global Perspective to Access to Transplantation at the 2022 Tandem Meeting. Transplantation and Cellular Therapy. 29(7). 410–417. 2 indexed citations

10.

Passweg, Jakob, Helen Baldomero, Fabio Ciceri, et al.. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation. 58(6). 647–658. 35 indexed citations

11.

Kara, Murat, et al.. (2022). The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P601- P606). Bone Marrow Transplantation. 57(S1). 458–461.

12.

Snowden, John A., Isabel Sánchez‐Ortega, Selim Corbacioglu, et al.. (2022). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation. 57(8). 1217–1239. 159 indexed citations breakdown →

13.

Morschhauser, Franck, Carmelo Carlo‐Stella, Michael Dickinson, et al.. (2021). Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). Blood. 138(Supplement 1). 128–128. 20 indexed citations

14.

Velasco, Roser, Eva Domingo‐Doménech, & Anna Sureda. (2021). Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. Cancers. 13(23). 6125–6125. 23 indexed citations

15.

Climent, Fina, Dolors Colomer, Mònica López‐Guerra, et al.. (2020). Clonal relationship in multisited mucosa‐associated lymphoid tissue lymphomas: a single‐centre experience. British Journal of Haematology. 192(6). 1020–1025.

16.

Sorigué, Marc, Santiago Mercadal, Sara Alonso, et al.. (2017). Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. Hematological Oncology. 35(4). 520–527. 11 indexed citations

17.

Pomares, Helena, Montserrat Arnán, Isabel Sánchez‐Ortega, Anna Sureda, & Rafael F. Duarte. (2016). Invasive fungal infections in AML / MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?. Mycoses. 59(8). 516–519. 36 indexed citations

18.

Peggs, K, Gary Cook, NH Russell, et al.. (2016). Reduced intensity conditioned allogeneic stem cell transplantation (RIC-Allo) as front-line therapy for mantle cell lymphoma (MCL): Results from the UK Phase II Mini Allo Study (CRUK: C7627/A9080). UCL Discovery (University College London). 2 indexed citations

19.

Kampen, Roel J.W. van, Carmen Canals, Harry C. Schouten, et al.. (2011). Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry. Journal of Clinical Oncology. 29(10). 1342–1348. 141 indexed citations

20.

Lahuerta, Juan José, María‐Victoria Mateos, Joaquín Martínez‐López, et al.. (2008). Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology. 26(35). 5775–5782. 193 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact